Treatment and prognosis of acute disseminated encephalomyelitis

Demyelinating Disorders of the Central Nervous System in Childhood

Volumn , Issue , 2011, Pages 212-222

  Waldman, Amy T ^a   Tardieu, Marc ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867740170     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511974373.020     Document Type: Chapter

References (63)

1. Tenembaum S, Chamoles N, Fejerman N. Acute disseminated encephalomyelitis: A long-term follow-up study of 84 pediatric patients. Neurology 2002;59:1224–1231.
2. Dale RC, de Sousa C, Chong WK, Cox TCS, Harding B, Neville BGR. Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 2000;123: 2407–2422.
3. Mikaeloff Y, Caridade G, Husson B, Suissa S, Tardieu M, on behalf of the Neuropediatric KIDSEP Study Group of the French Neuropediatric Society. Acute disseminated encephalomyelitis cohort study: Prognostic factors for relapse. Eur J Paediatr Neurol 2007;11:90–95.
4. Krupp LB, Banwell B, Tenembaum S. Consensus definitions proposed for pediatric multiple sclerosis and related disorders. Neurology 2007;68(Suppl 2): S7–S12.
5. Cohen I, Steiner-Birmanns B, Biram I, Abramsky O, Honigman S, Steiner I. Recurrence of acute disseminated encephalomyelitis at the previously affected brain site. Arch Neurol 2001;58:797–801.
6. Miller HG. Acute disseminated encephalomyelitis treated with ACTH. BMJ 1953;1(4803):177–182.
7. Rose AS, Kuzma JW, Kurtzke JF, Namerow NS, Sibley WA, Tourtellotte WW. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs placebo final report. Neurology 1970;20:1–59.
8. Pasternak JF, De Vivo DC, Prensky AL. Steroid-responsive encephalomyelitis in childhood. Neurology 1980;30:481.
9. Beck RW, Cleary PA, Anderson MM, et al. A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992;326:581–588.
10. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983;33:1444–1452.
11. Sebire G, Hollenberg H, Meyer L, Huault G, Landrieu P, Tardieu M. High dose methylprednisolone in severe acute transverse myelopathy. Arch Dis Child 1997;76:167–168.
12. Lahat E, Pillar G, Ravid S, Barzilai A, Etzioni A, Shahar E. Rapid recovery from transverse myelopathy in children treated with methylprednisolone. Pediatr Neurol 1998;19:279–282.
13. Straub J, Chofflon M, Delavelle J. Early high-dose intravenous methylprednisolone in acute disseminated encephalomyelitis: A successful recovery. Neurology 1997;49:1145–1147.
14. Anlar B, Basaran C, Kose G, et al. Acute disseminated encephalomyelitis in children: Outcome and prognosis. Neuropediatrics 2003;34:194–199.
15. Gupte G, Stonehouse M, Wassmer E, Coad NAG, Whitehouse WP. Acute disseminated encephalomyelitis: A review of 18 cases in childhood. J Paediatr Child Health 2003;39:336–342.
16. Hynson JL, Kornberg AJ, Colemen LT, Shield L, Harvey AS, Kean MJ. Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children. Neurology 2001;56:1308–1312.
17. Schmidt J, Gold R, Schonrock L, Zettl UK, Hartung HP, Toyka KV. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain 2000;123:1431–1441.
18. Sebire G, Delfraissy JF, Demotes-Mainard Oteifeh A, Emilie D, Tardieu M. Interleukin-13 and interleukin-4 act as interleukin-6 inducers in human microglial cells. Cytokine 1996;8:636–641.
19. Tischner D, Reichardt HM. Glucocorticoids in the control of neuroinflammation. Molec Cell Endocrinol 2007;275:62–70.
20. Tait AS, Butts CL, Sternberg EM. The role of glucocorticoids and progestins in inflammatory, autoimmune, and infectious disease. J Leuk Biol 2008;84:924–931.
21. van der Brandt J, Luhder F, McPherson KG, et al. Enhanced glucocorticoid receptor signaling in T cells impacts thymocyte apoptosis and adaptive immune responses. Am J Pathol 2007;170:1041–1053.
22. Thomas GS, Hussain IH. Acute disseminated encephalomyelitis: A report of six cases. Med J Malaysia 2004;59:324–351.
23. Tenembaum S, Chitnis T, Ness J, Hahn JS, for the International Pediatric MS Study Group. Acute disseminated encephalomyelitis. Neurology 2007;68:23–36.
24. Richards RN. Side effects of short-term oral corticosteroids. J Cut Med Surg 2008;12: 77–81.
25. Richards RN. Short-term corticosteroids and avascular necrosis: Medical and legal realities. Cutis 2007;80:343–348.
26. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 2001;44:1496–1503.
27. Leonard MB, Feldman HI, Shults J, Zemel BS, Foster BJ, Stallings VA. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoidsensitive nephrotic syndrome. N Engl J Med 2004;351:868–875.
28. Cohran VC, Griffiths M, Heubi JE. Bone mineral density in children exposed to chronic glucocorticoid therapy. Clin Pediatr 2008;47:469–475.
29. Munger KL, Levin LL, Hollis BW, et al. Serum 25- hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832–2838.
30. Hahn JS, Siegler DJ, Enzmann D. Intravenous gammaglobulin therapy in recurrent acute disseminated encephalomyelitis. Neurology 1996;46:1173–1174.
31. Suppiej A, Vittorini R, Fontanin M, et al. Acute disseminated encephalomyelitis in children: Focus on relapsing patients. Pediatr Neurol 2008;39:12–17.
32. Kleiman M, Brunquell P. Acute disseminated encephalomyelitis: Response to intravenous immunoglobulin? J Child Neurol 1995;10: 481–483.
33. Nishikawa M, Ichiyama T, Hayashi T, Ouchi K, Furukawa S. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. Pediatr Neurol 1999;21:583–586.
34. Abe Y, Horiuchi A, Miyake M, Kimura S. Anticytokine nature of natural human immunoglobulin: One possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev 1994;139:5–19.
35. Andersson U, Björk L, Skansén-Saphir U, Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev 1994;139:21–42.
36. Kurlander RJ. Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G. J Clin Invest 1980;66:773–781.
37. Kurlander RJ, Hall J. Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J Clin Invest 1986;77:2010–2018.
38. Hansen MB, Svenson M, Diamant M, Bendtzen K. High-affinity IgG autoantibodies to IL-6 in sera of normal individuals are competitive inhibitors of IL-6 in vitro. Cytokine 1993;5:72–80.
39. Svenson M, Hansen MB, Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest 1993;92:2533–2539.
40. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994;94:1729–1735.
41. Dietrich G, Kazatchkine MD. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated crossreactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest 1990;85:620–625.
42. Obando I, Duran I, Martin-Rosa L, Maria J, Garcia-Martin FJ. Aseptic meningitis due to administration of intravenous immunoglobulin with an usually high number of leukocytes in cerebrospinal fluid. Pediatr Emerg Care 2002;18:429–432.
43. Shahar E, Andraus J, Savitzki D, Pilar G, Zeinik N. Outcome of severe encephalomyelitis in children: Effect of high-dose methylprednisolone and immunoglobulins. J Child Neurol 2002;17:810–814.
44. Pradhan S, Gupta R, Shashank S, Pandey N. Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. J Neurol Sci 1999;165:56–61.
45. Anonymous. Assessment of plasmapheresis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1996;47:840–843.
46. Weinshenker BG. Therapeutic plasma exchange for acute inflammatory demyelinating syndromes of the central nervous system. J Clin Apheresis 1999;14:144–148.
47. Weinshenker BG, O’Brien PC, Petterson TM, et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999;46:878–886.
48. Weiner HL, Dau PC, Khatri BO, et al. Double-blind study of true vs. sham plasma exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989;39:1143–1149.
49. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: Predictors of response. Neurology 2002;58:143–146.
50. Khurana DS, Melvin JJ, Kothare SV, et al. Acute disseminated encephalomyelitis in children: Discordant neurologic and neuroimaging abnormalities and response to plasmapheresis. Pediatrics 2005;116:431–436.
51. Balestri P, Grosso S, Acquaviva A, Bernini M. Plasmapheresis in a child affected by acute disseminated encephalomyelitis. Brain Dev 2000;22:123–126.
52. Miyazawa R, Hikima A, Takano Y, Arakawa H, Tomomasa T, Morikawa A. Plasmapheresis in fulminant acute disseminated encephalomyelitis. Brain Dev 2001;23:424–426.
53. Hung KL, Liao HT, Tsai ML. The spectrum of postinfectious encephalomyelitis. Brain Dev 2001;23:42–45.
54. Murthy SNK, Faden HS, Cohen ME, Bakshi R. Acute disseminated encephalomyelitis in children. Pediatrics 2002;110:21–27.
55. Markus R, Brew BJ, Turner J, Pell M. Successful outcome with aggressive treatment of acute haemorrhagic leukoencephalitis. J Neurol Neurosurg Psychiatry 1997;63:551.
56. Idrissova ZR, Boldyreva MN, Dekonenko EP, et al. Acute disseminated encephalomyelitis in children: Clinical features and HLA-DR linkage. Eur J Neurol 2003;10:537–546.
57. Hahn CD, Miles BS, MacGregor DL, Blaser SI, Banwell BL, Hetherington CR. Neurocognitive outcome after acute disseminated encephalomyelitis. PediatrNeurol 2003;29:117–123.
58. Omata T, Arai H, Tanabe Y. Child with acute disseminated encephalomyelitis (ADEM) initially presenting with psychiatric symptoms. [Japanese] No to Hattatsu [Brain and Development] 2008;40: 465–468.
59. Brass SD, Caramanos Z, Santos C, Dilenge ME, Lapierre Y, Rosenblatt B. Multiple sclerosis vs. acute disseminated encephalomyelitis in childhood. PediatrNeurol 2003;29:227–231.
60. Kuperan S, Ostrow P, Landi MK, Bakshi R. Acute hemorrhagic leukoencephalitis vs. ADEM: FLAIR MRI and neuropathology findings. Neurology 2003;60:721–722.
61. Leake JA, Albani S, Kao AS, et al. Acute disseminated encephalomyelitis in childhood: Epidemiologic, clinical, and laboratory features. Pediatr Infect Dis J 2004;23:756–764.
62. Kimura S, Nezu A, Ohtsuki N, Kobayashi T, Osaka H, Uehara S. Serial magnetic resonance imaging in children with postinfectious encephalitis. Brain Dev 1996;18:461–465.
63. Murthy JMK, Yangala R, Meena AK, Reddy J. Acute disseminated encephalomyelitis: Clinical and MRI study from south India. J Neurol Sci 1999;165: 133–138.